1. Home
  2. SOAR vs SNOA Comparison

SOAR vs SNOA Comparison

Compare SOAR & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Volato Group Inc.

SOAR

Volato Group Inc.

N/A

Current Price

$0.33

Market Cap

5.3M

Sector

Finance

ML Signal

N/A

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

N/A

Current Price

$2.42

Market Cap

6.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOAR
SNOA
Founded
2021
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
6.1M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
SOAR
SNOA
Price
$0.33
$2.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.1M
10.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,288,000.00
Revenue This Year
N/A
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
$0.28
N/A
Revenue Growth
N/A
12.19
52 Week Low
$0.28
$1.77
52 Week High
$4.36
$6.92

Technical Indicators

Market Signals
Indicator
SOAR
SNOA
Relative Strength Index (RSI) 38.77 33.97
Support Level $0.28 N/A
Resistance Level $0.73 $3.85
Average True Range (ATR) 0.04 0.16
MACD 0.02 -0.02
Stochastic Oscillator 37.19 16.34

Price Performance

Historical Comparison
SOAR
SNOA

About SOAR Volato Group Inc.

Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: